Department of Gastroenterology, Marmara University, School of Medicine, Istanbul 34899, Turkey.
J Crohns Colitis. 2011 Oct;5(5):402-6. doi: 10.1016/j.crohns.2011.03.011. Epub 2011 Apr 15.
Interaction of the receptor for advanced glycation endproducts (RAGE) with its ligands results in expression of inflammatory mediators, activation of NF-κB, and induction of oxidative stress, all of which have been implicated in the pathogenesis of inflammatory bowel diseases (IBD). Soluble receptor for advanced glycation endproducts (sRAGE) has recently emerged as a reliable biomarker of inflammation in numerous RAGE-mediated disorders.
To assess sRAGE levels in adult patients with IBD.
Serum was collected from adult patients with Crohn's disease (CD, 56 patients), ulcerative colitis (UC, 60 patients), and healthy controls (HC, 113 subjects). Levels of sRAGE were determined by enzyme-linked immunosorbent assay.
Serum sRAGE levels were elevated in IBD compared to HC and were higher in UC patients compared to CD and HC. Levels of sRAGE were significantly higher in the serum of UC patients with active disease compared to patients with inactive disease, but no association with the Montreal Classification was evident. Serum sRAGE was lower in CD patients with biological therapies.
These findings suggest that serum levels of sRAGE are altered in patients with intestinal inflammation and may reflect distinct immunoinflammatory pathogenesis of UC and CD.
评估炎症性肠病（IBD）成年患者的可溶性晚期糖基化终产物受体（sRAGE）水平。
收集克罗恩病（CD，56 例）、溃疡性结肠炎（UC，60 例）和健康对照者（HC，113 例）的成年患者血清。采用酶联免疫吸附试验测定 sRAGE 水平。
与 HC 相比，IBD 患者血清 sRAGE 水平升高，UC 患者高于 CD 和 HC。活动期 UC 患者血清 sRAGE 水平显著高于缓解期患者，但与蒙特利尔分类无明显关联。接受生物治疗的 CD 患者血清 sRAGE 水平较低。
这些发现表明，肠道炎症患者的血清 sRAGE 水平发生改变，可能反映了 UC 和 CD 的不同免疫炎症发病机制。
